Literature DB >> 15448981

Tobacco smoke-dependent changes in cytochrome P450 1A1, 1A2, and 2E1 protein expressions in fetuses, newborns, pregnant rats, and human placenta.

Piotr Czekaj1, Anna Wiaderkiewicz, Ewa Florek, Ryszard Wiaderkiewicz.   

Abstract

Tobacco smoke (TS) was described as a mixture of numerous cytochrome P450 (P450) substrates, inducers, and inhibitors. These inducers and inhibitors may modify drug clearance and xenobiotic or endogenous metabolism affecting P450s expression. In the present study, the effect of gestation and TS on: (1) cytochrome P450 CYP1A1, CYP1A2, and CYP2E1 protein expressions, and (2) cytochrome P450-linked microsomal enzyme activities, were studied in fetal rat liver, rat, and human placenta and in newborn and adult rat hepatic and extrahepatic tissues. Non-pregnant and pregnant 4-month-old female Wistar rats were exposed to TS (500, 1,000, or 1,500 mg carbon monoxide per m(3) air) in a toxicological chamber for 3 weeks (6 h daily, 5 days weekly). Human placentas were sampled from non-smoking, passive smoking, or active smoking primiparas. The efficacy of exposure was assessed by measuring urine cotinine levels. The TS-dependent inductory effect on the expression of CYP1A1 and 1A2 and related monooxygenase activities, and the inhibitory/inductory effect on CYP2E1 expression in rat tissues were observed. Pregnancy was associated with decreased levels of constitutive CYP1A1 and 2E1 in hepatic and extrahepatic tissues, TS-inducible CYP1A2 expression in the liver, and CYP1A1 expression in lungs and heart, but had no inhibitory effect on TS-inducible CYP1A1 and 2E1 expression, EROD, and P450-cooperated enzyme activities in the liver, kidney, and, in the latter case, in the heart. The presence of TS-induced CYP1A1 protein was confirmed in rat and human placenta and showed in newborn liver and lungs. CYP1A2 and 2E1 proteins were detectable in fetal rat liver. It was concluded that the expression of CYP1A1, 1A2, and 2E1, which metabolize some drugs and activate carcinogens, is controlled by age-, pregnancy-, and tissue-specific regulatory mechanisms in rats. Gestational differences in the regulation of expression of CYP1A subfamily members are not excluded. CYP1A1 and 2E1, but not CYP1A2 inductory mechanisms seem to be functional in fetal liver at day 21 of pregnancy but they appeared to be uninducible under a TS exposure. In TS-exposed pregnant females and fetuses the effects of metabolic activation of CYP1A1 and 1A2 substrates might be reduced because of lower CYP expressions or poor induction, respectively.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15448981     DOI: 10.1007/s00204-004-0607-7

Source DB:  PubMed          Journal:  Arch Toxicol        ISSN: 0340-5761            Impact factor:   5.153


  25 in total

1.  Pregnancy decreases rat CYP1A2 activity and expression.

Authors:  Alysa A Walker; Leslie Dickmann; Nina Isoherranen
Journal:  Drug Metab Dispos       Date:  2010-10-04       Impact factor: 3.922

Review 2.  Pharmacokinetics in neonatal prescribing: evidence base, paradigms and the future.

Authors:  Kate O'Hara; Ian M R Wright; Jennifer J Schneider; Alison L Jones; Jennifer H Martin
Journal:  Br J Clin Pharmacol       Date:  2015-10-26       Impact factor: 4.335

3.  Pharmacogenomics of maternal tobacco use: metabolic gene polymorphisms and risk of adverse pregnancy outcomes.

Authors:  Kjersti Aagaard-Tillery; Catherine Y Spong; Elizabeth Thom; Baha Sibai; George Wendel; Katharine Wenstrom; Philip Samuels; Hyagriv Simhan; Yoram Sorokin; Menachem Miodovnik; Paul Meis; Mary J O'Sullivan; Deborah Conway; Ronald J Wapner
Journal:  Obstet Gynecol       Date:  2010-03       Impact factor: 7.661

4.  Effects of fluvastatin and cigarette smoking on CYP2C9 activity measured using the probe S-warfarin.

Authors:  Myong-Jin Kim; Anne N Nafziger; Angela D M Kashuba; Julia Kirchheiner; Steffen Bauer; Andrea Gaedigk; Joseph S Bertino
Journal:  Eur J Clin Pharmacol       Date:  2006-04-27       Impact factor: 2.953

5.  Population pharmacokinetics and the pharmacokinetic/pharmacodynamic relationship of riociguat in patients with pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension.

Authors:  Soundos Saleh; Corina Becker; Reiner Frey; Wolfgang Mück
Journal:  Pulm Circ       Date:  2016-03       Impact factor: 3.017

6.  Assessment of the effects of hepatic impairment and smoking on the pharmacokinetics of a single oral dose of the soluble guanylate cyclase stimulator riociguat (BAY 63-2521).

Authors:  Reiner Frey; Corina Becker; Sigrun Unger; Anja Schmidt; Georg Wensing; Wolfgang Mück
Journal:  Pulm Circ       Date:  2016-03       Impact factor: 3.017

Review 7.  Pharmacokinetic Drug Interactions with Tobacco, Cannabinoids and Smoking Cessation Products.

Authors:  Gail D Anderson; Lingtak-Neander Chan
Journal:  Clin Pharmacokinet       Date:  2016-11       Impact factor: 6.447

8.  Brain oxidative damage restored by Sesbania grandiflora in cigarette smoke-exposed rats.

Authors:  Thiyagarajan Ramesh; Chandrabose Sureka; Shanmugham Bhuvana; Vavamohaideen Hazeena Begum
Journal:  Metab Brain Dis       Date:  2015-01-27       Impact factor: 3.584

Review 9.  Environmental influences on epigenetic profiles.

Authors:  Melissa A Suter; Kjersti M Aagaard-Tillery
Journal:  Semin Reprod Med       Date:  2009-08-26       Impact factor: 1.303

10.  The amplex red/horseradish peroxidase assay requires superoxide dismutase to measure hydrogen peroxide in the presence of NAD(P)H.

Authors:  Vladimir Mishin; Diane E Heck; Debra L Laskin; Jeffrey D Laskin
Journal:  Free Radic Res       Date:  2020-10-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.